The 2-OS and 4-OS rates for patients with neuroblastoma with amplified MYCN were 67.1 and 54.4%, respectively, and significantly lower than the 83.8 and 72.0% for patients without MYCN amplification (P=0.0117). Here, MYCN is linked to neuroblastoma.